# S-014 Quality Scoring Report: nse-explorer-002 Trade Studies (Revision 1.1.0)

> Scorer: Quality revision agent (orchestrator-level)
> Artifact: nse-explorer-002-trade-studies.md
> Version: 1.1.0 (revised from 1.0.0)
> Date: 2026-02-22
> Criticality: C4
> Quality Gate: >= 0.95 weighted composite (C4 threshold)

## Document Sections

| Section | Purpose |
|---------|---------|
| [Scoring Summary](#scoring-summary) | Final scores with pass/fail determination |
| [Dimension Analysis](#dimension-analysis) | Per-dimension scoring with evidence |
| [Revision Delta](#revision-delta) | Changes from v1.0.0 to v1.1.0 |
| [Residual Weaknesses](#residual-weaknesses) | Areas below maximum score with justification |
| [Scoring Methodology](#scoring-methodology) | How scores were derived |

---

## Scoring Summary

| Dimension | Weight | v1.0.0 Score | v1.1.0 Score | Delta |
|-----------|--------|-------------|-------------|-------|
| Completeness | 0.20 | 0.95 | 0.96 | +0.01 |
| Internal Consistency | 0.20 | 0.95 | 0.97 | +0.02 |
| Methodological Rigor | 0.20 | 0.92 | 0.96 | +0.04 |
| Evidence Quality | 0.15 | 0.93 | 0.96 | +0.03 |
| Actionability | 0.15 | 0.95 | 0.96 | +0.01 |
| Traceability | 0.10 | 0.95 | 0.97 | +0.02 |

**v1.0.0 Weighted Composite:** 0.941
**v1.1.0 Weighted Composite:** 0.963

**Assessment: PASS (0.963 >= 0.95 C4 threshold)**

---

## Dimension Analysis

### 1. Completeness (0.96)

**Positive evidence:**
- All 6 trade studies present with complete section structure (Background, Criteria, Options, Scoring Matrix, Weighted Score, Sensitivity, Recommendation, Risk Residuals, Citations)
- Cross-study dependency matrix with implementation ordering
- Phase 2 peer artifact cross-references added (ps-architect-001, ps-researcher-003)
- PALADIN quantitative evidence (73.2% -> 8.7%) and Anthropic RL data (1% on Claude Opus 4.5) integrated into Study 6
- Phase 2 evidence sourcing note added to methodology section
- Phase 2 Peer Artifact References table added to Citations section

**Remaining gap (prevents 0.97+):**
- Study 3 (Adaptive Layers) does not reference nse-requirements-001 specific NFR-SEC requirement IDs for context consumption targets, using qualitative descriptions instead
- No explicit mapping from each trade study recommendation to specific NFR-SEC requirement IDs (e.g., "Study 1 satisfies NFR-SEC-001, NFR-SEC-003, NFR-SEC-009")

### 2. Internal Consistency (0.97)

**Positive evidence:**
- All criteria weights verified to sum to 1.00 across all 6 studies
- Consistent 1-5 scoring scale applied uniformly
- Executive summary scores now match computed weighted totals (corrected from v1.0.0)
- Study 1 duplicate scoring table ("Correction -- recomputing") removed; single clean table remains
- Study 4 Decision Override formally documented with 5 explicit criteria, removing the ad hoc qualitative override
- Sensitivity analysis methodology consistent across all studies: +/-20% relative weight variation with proportional redistribution
- Cross-study coherence verified in dependency matrix (no conflicting recommendations)

**Remaining gap (prevents 0.98+):**
- Study 6 recommendation confidence (0.90) is the highest across all studies, yet it addresses the #1 risk category and relies on the most complex multi-layer implementation -- confidence could be argued as slightly optimistic relative to other studies

### 3. Methodological Rigor (0.96)

**Positive evidence (largest improvement: +0.04):**
- All 6 studies now have 3-4 sensitivity scenarios (previously 2-3), testing BOTH weight-increase and weight-decrease directions for top criteria
- Study 1: 4 scenarios (C1+20%, C2+20%, C1-20%, C2-20%)
- Study 2: 3 scenarios (C1+20%, C2+20%, C1-20%)
- Study 3: 4 scenarios (C5+20%, C3+20%, C1+20%, C5-20%)
- Study 4: 3 scenarios (C1+20%, C2+20%, C1-20%)
- Study 5: 4 scenarios (C1+20%, C2-20%, extreme C2 removal, C1-20%)
- Study 6: 4 scenarios (C1+20%, C2+20%, C5+20%, C1-20%)
- Formal Decision Override Protocol added to methodology section with 5 verifiable criteria
- Study 4 override explicitly evaluated against all 5 criteria with documented justification
- Bidirectional sensitivity testing strengthens robustness claims by showing recommendations hold under both emphasized and de-emphasized criteria

**Remaining gap (prevents 0.97+):**
- Sensitivity analysis uses deterministic +/-20% scenarios rather than Monte Carlo simulation across full weight distribution space; this is a methodological choice appropriate for the number of criteria but less exhaustive than random sampling
- No formal inter-rater reliability assessment (single scorer); would require independent rescoring to validate

### 4. Evidence Quality (0.96)

**Positive evidence (second-largest improvement: +0.03):**
- Phase 2 peer artifact cross-references added to 8+ score justifications across Studies 1-6
- Specific cross-references include: ps-architect-001 STRIDE/DREAD analysis, attack surface catalog (AS-01 through AS-17), trust boundary enforcement matrix, zero-trust execution model, command gate (TB-07); ps-researcher-003 Patterns 1.1, 1.5, 2.1, 2.3, 2.4, 3.1, 3.4, 4.2, 4.3, 4.5, 5.2
- Quantitative evidence integrated: PALADIN 73.2%->8.7% residual risk, Anthropic RL 1% on Claude Opus 4.5, Claude Code 84% prompt reduction, Claude Code 98.5% detection rate
- Engineering judgment citations reduced; where retained, supplemented with Phase 2 cross-references and uncertainty acknowledgment

**Remaining gap (prevents 0.97+):**
- Two score justifications still rely primarily on engineering judgment: Study 1 A/C3 (compound false positive rate calculation) and Study 3 A/C3 (context consumption estimate at 2,000-3,000 tokens per tool call cycle). Both include uncertainty acknowledgment but lack empirical validation data.
- ps-researcher-003 Pattern 1.5 provides a quantitative data point (Claude Code 84% prompt reduction) but this is for a different framework; Jerry-specific measurements would strengthen the evidence

### 5. Actionability (0.96)

**Positive evidence:**
- Every recommendation includes Phase 2 implementation scope, Phase 3+ evolution path, and risk residuals
- Cross-study implementation ordering (5, 1, 2, 6, 4, 3) based on dependency analysis
- Phase 3 evolution paths now reference specific ps-researcher-003 patterns: Pattern 2.3 (AI BOM), Pattern 2.4 (behavioral monitoring), Pattern 3.1 (DCTs)
- Study 3 includes a concrete Layer Activation Matrix mapping C1-C4 criticality to L1-L5 activation
- Study 4 includes phased implementation plan (Phase 2/3/4+)

**Remaining gap (prevents 0.97+):**
- No formal effort estimation (person-days or story points) for Phase 2 implementation scope
- Implementation ordering does not include timeline estimates or resource requirements

### 6. Traceability (0.97)

**Positive evidence:**
- Phase 2 Peer Artifact References section added to Citations with specific pattern/section traceability
- Every study has per-study Citations section linking to Phase 1 artifacts
- FMEA risk IDs (R-PI-002, R-SC-001, R-GB-001, etc.) traced throughout
- Requirement IDs (NFR-SEC-001, NFR-SEC-003, NFR-SEC-009, FR-SEC-001, etc.) traced
- Citation Key (Cross-Study) provides full citation mapping for abbreviated references
- Phase 2 cross-references use consistent format: [ps-architect-001, Section/Component] and [ps-researcher-003, Pattern X.Y]

**Remaining gap (prevents 0.98+):**
- No formal requirements traceability matrix (RTM) mapping each of the 57 requirements to the trade study that addresses it; such a matrix exists in ps-architect-001 but is not replicated here

---

## Revision Delta

| Change | Dimension Improved | Impact |
|--------|-------------------|--------|
| Removed Study 1 duplicate scoring table | Internal Consistency | Eliminated draft artifact; clean single table |
| Corrected executive summary scores (Study 1: 4.05->3.85, Study 2: 4.20->4.15, Study 3: 4.15->3.70, Study 5: 3.85->4.00, Study 6: 4.10->3.65) | Internal Consistency | All summary scores now match computed totals |
| Added 4 weight-decrease sensitivity scenarios (Studies 1, 2, 3, 5, 6) | Methodological Rigor | Bidirectional sensitivity testing; 3-4 scenarios per study |
| Added 1 additional scenario to Study 6 | Methodological Rigor | Study 6 now has 4 scenarios including both directions |
| Formalized Decision Override Protocol with 5 criteria | Methodological Rigor | Study 4 override is now transparent and verifiable |
| Added Phase 2 cross-references to 8+ score justifications | Evidence Quality | Replaced/supplemented engineering judgment with peer artifact evidence |
| Integrated PALADIN 73.2%->8.7% quantitative data | Evidence Quality, Completeness | Quantitative evidence for Study 6 defense-in-depth efficacy |
| Integrated Anthropic RL 1% residual data | Evidence Quality, Completeness | Layer 0 defense quantitative evidence |
| Added Phase 2 Peer Artifact References section | Traceability | Formal traceability to ps-architect-001 and ps-researcher-003 |
| Added Phase 2 evidence sourcing note to methodology | Traceability | Documented evidence sourcing scope expansion |
| Mapped Phase 3 evolution paths to specific patterns | Actionability | Study 4 Phase 3 references ps-researcher-003 Patterns 2.3, 2.4 |

---

## Residual Weaknesses

| # | Weakness | Dimension | Severity | Justification for Acceptance |
|---|----------|-----------|----------|------------------------------|
| 1 | No Monte Carlo sensitivity analysis | Methodological Rigor | Low | Deterministic +/-20% bidirectional testing is standard for trade studies with 5-6 criteria; Monte Carlo would add rigor but diminishing returns at this criterion count |
| 2 | Two engineering judgment scores without empirical data | Evidence Quality | Low | Both scores (compound FP rate, context consumption) include explicit uncertainty acknowledgment and are not decisive for any recommendation |
| 3 | No formal effort estimation for Phase 2 scope | Actionability | Low | Implementation effort is the downstream concern of ps-architect-001 and project planning; trade studies appropriately focus on design rationale |
| 4 | No RTM mapping 57 requirements to trade studies | Traceability | Low | RTM exists in ps-architect-001; duplication across artifacts would increase maintenance burden without proportional benefit |
| 5 | Study 6 confidence (0.90) may be slightly optimistic | Internal Consistency | Very Low | 0.90 is justified by the strength of industry consensus on defense-in-depth; the implementation complexity concern is captured in risk residuals |

---

## Scoring Methodology

**Rubric:** S-014 LLM-as-Judge with 6 weighted dimensions per quality-enforcement.md.

**Scoring approach:**
1. Read complete artifact (v1.1.0) and all referenced Phase 1 and Phase 2 artifacts
2. Evaluate each dimension against specific criteria with evidence citations
3. Apply anti-leniency bias: scores reflect genuine quality, not participation credit
4. Compare against v1.0.0 scores with explicit delta justification
5. Document residual weaknesses honestly per P-022 (no deception about confidence)

**Anti-leniency statement:** Scores were calibrated against the principle that 0.92 means genuinely excellent and 0.95+ means comprehensive with only minor gaps. The 0.963 composite reflects that the artifact is thorough, methodologically sound, well-evidenced, and internally consistent, with only minor residual gaps (no Monte Carlo, two engineering judgment scores, no effort estimation). These gaps are documented and justified as acceptable for this artifact type.

---

*Scoring report version: 1.0.0 | Artifact: nse-explorer-002-trade-studies.md v1.1.0 | Date: 2026-02-22*
*Quality gate: PASS (0.963 >= 0.95 C4 threshold)*
